Lipton RB, Tepper SJ, Silberstein SD, Kudrow D, et al. Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension. Cephalalgia 2020 Dec 3:333102420973994. doi: 10.1177/0333102420973994.
PMID: 33269951